Northstrive Biosciences, a subsidiary of PMGC Holdings Inc., has initiated Phase II of its AI drug development program with Yuva Biosciences. This phase focuses on using YuvaBio’s AI platform, MitoNova™, to identify small molecule candidates that improve mitochondrial health for obesity and cardiac diseases. The collaboration aims to screen a vast library of molecules and predict their effectiveness in boosting mitochondrial function.
This development holds promise for advancing the treatment of cardiometabolic diseases. Targeting mitochondrial health offers a novel approach to addressing the underlying mechanisms of these conditions. By focusing on mitochondrial function, the collaboration aims to develop therapies that not only treat symptoms but potentially improve overall metabolic health and preserve muscle mass, which is a significant concern for patients undergoing weight loss treatments.
Technically, YuvaBio will employ its AI platform to analyze the chemical and bioactivity properties of a large number of molecules. The most promising candidates will be selected for biological validation. The collaboration aims to compile a list of synthetic compounds specifically designed for muscle preservation and improved metabolic health. This streamlined approach, powered by AI, accelerates the drug discovery process and potentially increases the chances of identifying effective treatments.
This collaboration signals a significant step toward developing innovative treatments for obesity and cardiac diseases. The use of AI-driven technology like MitoNova™ could revolutionize drug discovery in the cardiometabolic space, ultimately leading to more effective and targeted therapies for patients. Further validation and development of these identified molecules will be critical milestones to watch.
